Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:3765608.
doi: 10.1155/2016/3765608. Epub 2016 Apr 21.

Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates

Affiliations
Review

Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates

Eva Königshausen et al. Biomed Res Int. 2016.

Abstract

Primary focal segmental glomerulosclerosis (FSGS) is a major cause of the nephrotic syndrome and often leads to end-stage renal disease. This review focuses on circulating permeability factors in primary FSGS that have been implicated in the pathogenesis for a long time, partly due to the potential recurrence in renal allografts within hours after transplantation. Recently, three molecules have been proposed as a potential permeability factor by different groups: the soluble urokinase plasminogen activator receptor (suPAR), cardiotrophin-like cytokine factor-1 (CLCF-1), and CD40 antibodies. Both CLCF-1 and CD40 antibodies have not been validated by independent research groups yet. Since the identification of suPAR, different studies have questioned the validity of suPAR as a biomarker to distinguish primary FSGS from other proteinuric kidney diseases as well as suPAR's pathogenic role in podocyte damage. Researchers have suggested that cleaved molecules of suPAR have a pathogenic role in FSGS but further studies are needed to determine this role. In future studies, proposed standards for the research of the permeability factor should be carefully followed. The identification of the permeability factor in primary FSGS would be of great clinical relevance as it could influence potential individual treatment regimen.

PubMed Disclaimer

References

    1. Collins A. J., Foley R. N., Herzog C., et al. US renal data system 2010 annual data report. American Journal of Kidney Diseases. 2011;57(1, supplement 1, article A8):e1–e526. doi: 10.1053/j.ajkd.2010.10.007. - DOI - PubMed
    1. D'Agati V. D., Fogo A. B., Bruijn J. A., Jennette J. C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. American Journal of Kidney Diseases. 2004;43(2):368–382. doi: 10.1053/j.ajkd.2003.10.024. - DOI - PubMed
    1. D'Agati V. D., Kaskel F. J., Falk R. J. Focal segmental glomerulosclerosis. The New England Journal of Medicine. 2011;365(25):2398–2411. doi: 10.1056/nejmra1106556. - DOI - PubMed
    1. Fogo A. B. Causes and pathogenesis of focal segmental glomerulosclerosis. Nature Reviews Nephrology. 2015;11(2):76–87. doi: 10.1038/nrneph.2014.216. - DOI - PMC - PubMed
    1. Kitiyakara C., Kopp J. B., Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Seminars in Nephrology. 2003;23(2):172–182. doi: 10.1053/snep.2003.50025. - DOI - PubMed